Details of the Drug Reposition

General Information of This Drug (ID: DM9LNXS)

Drug Name
ARI-3037MO   DM9LNXS

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Hypertriglyceridemia DIS7SN6U 5C80.1 Phase 2 [1]
Dyslipidemia DISUYOOU 5C80-5C81 Phase 2 [2]
Cardiovascular disease DIS2IQDX BA00-BE2Z Phase 2 [1]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02250105) Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe ( 00 mg/dl) Hypertriglyceridemia. U.S. National Institutes of Health.